IP is essential, and should be used to improve access #bio2012

In the Scientific American Worldview panel, Biocon’s Kiran Mazumdar Shaw opined on intellectual property in biotechnology — IP is essential for biotechnology, and should be used to improve access rather than to drive high prices. She elaborated that improving access with affordable medicines can yield higher profits than serving smaller markets with higher prices.


   No Comments yet


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!